Vimarsana
Biggest News Aggregation in the World

Page 13 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

Knights of Columbus Asset Advisors LLC Takes $77,000 Position in BeiGene, Ltd. (NASDAQ:BGNE) - Vimarsana News

Knights of Columbus Asset Advisors LLC Takes $77,000 Position in BeiGene, Ltd. (NASDAQ:BGNE)

Knights of Columbus Asset Advisors LLC bought a new stake in BeiGene, Ltd. (NASDAQ:BGNE – Free Report) in the first quarter, Holdings Channel reports. The institutional investor bought 357 shares of the company’s stock, valued at approximately $77,000. A number of other institutional investors and hedge funds have also made changes to their positions in […]

BeiGene Gets Positive CHMP Opinion for Tislelizumab to Treat Serious Esophageal Cancer - Vimarsana News

BeiGene Gets Positive CHMP Opinion for Tislelizumab to Treat Serious Esophageal Cancer

By Chris Wack BeiGene said Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion...

BeiGene, Ltd. (NASDAQ:BGNE) Shares Acquired by China Universal Asset Management Co. Ltd. - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE – Free Report) by 18.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 577 shares of the company’s stock after purchasing an additional 91 shares […]

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation? - Vimarsana News

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Key Insights BeiGene's estimated fair value is US$317 based on 2 Stage Free Cash Flow to Equity BeiGene is estimated to...

Source: yahoo.com
With End of Alliance, Novartis Walks Away From Once Hot Cancer Target - Vimarsana News

With End of Alliance, Novartis Walks Away From Once Hot Cancer Target

Novartis and BeiGene ended their partnership on a cancer immunotherapy for a target called TIGIT. Though BeiGene describes the termination as mutual, it comes before Novartis would need to pump more money into the alliance even as questions linger about TIGIT as a cancer target.